Randomized, Double-Blind, Placebo-Controlled, Multinational Phase 3 Trial Of Iseganan In Prevention Of Ventilator-Associated Pneumonia

NCT00118781 Phase 2/Phase 3 TERMINATED

This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and mechanically ventilated and survive for up to 14 days.

Details

Lead sponsor	IntraBiotics Pharmaceuticals
Phase	Phase 2/Phase 3
Status	TERMINATED
Enrolment	900
Start date	2003-09
Completion	2004-06

Conditions

• Pneumonia

Interventions

• iseganan hydrochloride

Primary outcomes

• The primary objectives of this trial are to evaluate the safety and efficacy of iseganan when administered to intubated patients receiving mechanical ventilation.

Countries

United States